G1 Therapeutics Inc (GTHX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
56
About the Report
About the Report
Summary
G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc, is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutics for the treatment of cancer. The company's pipeline products include trilaciclib (G1T28), a CDK4/6 inhibitor to preserve hematopoietic stem cell and immune system function during chemotherapy; G1T38, an oral CDK4/6 inhibitor served as backbone therapy for multiple combination regimens; Lerociclib; and G1T48, an oral selective estrogen receptor degrader. G1 Therapeutics discovers new small molecule-based methods that prevent the hematological side effects of cancer chemotherapy and exposure to ionizing radiation. The company also develops small molecules to target specific proteins associated with cell proliferation and growth. It operates through its laboratory located in Research Triangle Park. G1 Therapeutics is headquartered in Research Triangle Park, North Carolina, the US.
G1 Therapeutics Inc (GTHX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
G1 Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
G1 Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
G1 Therapeutics Raises USD47 Million in Series C Financing 12
G1 Therapeutics Raises USD33 Million in Series B Financing 14
G1 Therapeutics Raises USD 12.5 Million In Series A Financing 16
G-Zero Therapeutics Raises USD 1.3 Million In Venture Financing 17
G1 Therapeutics Raises USD 0.6 Million In Seed Financing 18
G1 Therapeutics Raises USD 0.8 Million In Venture Financing 19
Partnerships 20
GeneCentric Therapeutics Enters into Research Partnership with G1 Therapeutics 20
G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 21
G1 Therapeutics Enters into Agreement with Genentech 22
Licensing Agreements 23
G1 Therapeutics Amends Licensing Agreement With Board Of Trustees Of The University Of Illinois 23
Equity Offering 24
G1 Therapeutics Raises USD207 Million in Public Offering of Shares 24
G1 Therapeutics Raises USD115.3 Million in Public Offering of Shares 26
G1 Therapeutics Raises USD116.7 Million in IPO 28
G1 Therapeutics Inc-Key Competitors 30
G1 Therapeutics Inc-Key Employees 31
G1 Therapeutics Inc-Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Aug 08, 2018: G1 Therapeutics provides second quarter 2018 corporate and financial update 33
May 03, 2018: G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update 35
Feb 21, 2018: G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results 36
Nov 08, 2017: G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights 38
Aug 09, 2017: G1 Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 39
Corporate Communications 41
Jul 09, 2018: G1 Therapeutics Appoints John Demaree As Chief Commercial Officer And Stillman Hanson As General Counsel 41
Jun 08, 2018: G1 Therapeutics Announces Appointment of New Members to the Board of Directors 42
Dec 18, 2017: G1 Therapeutics Added to Nasdaq Biotechnology Index 43
Sep 18, 2017: G1 Therapeutics Added to Russell 2000, 3000 and Microcap Indexes 44
Jul 13, 2017: G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors 45
Product News 46
06/02/2018: G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 46
05/16/2018: G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology Annual Meeting 48
04/16/2018: G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer 49
01/10/2017: G1 Therapeutics Initiates Phase 1b/2a Trial of G1T38 in Estrogen Receptor-Positive Breast Cancer 50
Clinical Trials 51
Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting 51
Mar 29, 2017: G1 Therapeutics Announces Presentation on G1T38 at the 2017 American Association for Cancer Research Annual Meeting 52
Mar 29, 2017: G1 Therapeutics Announces Presentation on G1T48 at the 2017 American Association for Cancer Research Annual Meeting 53
Jan 10, 2017: G1 Therapeutics Initiates Phase 2 trial of Trilaciclib in Triple-Negative Breast Cancer 54
Jan 10, 2017: G1 Therapeutics to Start Phase I Study of G1T48 in Q4 2017 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
List of Figure
List of Figures
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
G1 Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
G1 Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
G1 Therapeutics Raises USD47 Million in Series C Financing 12
G1 Therapeutics Raises USD33 Million in Series B Financing 14
G1 Therapeutics Raises USD 12.5 Million In Series A Financing 16
G-Zero Therapeutics Raises USD 1.3 Million In Venture Financing 17
G1 Therapeutics Raises USD 0.6 Million In Seed Financing 18
G1 Therapeutics Raises USD 0.8 Million In Venture Financing 19
GeneCentric Therapeutics Enters into Research Partnership with G1 Therapeutics 20
G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 21
G1 Therapeutics Enters into Agreement with Genentech 22
G1 Therapeutics Amends Licensing Agreement With Board Of Trustees Of The University Of Illinois 23
G1 Therapeutics Raises USD207 Million in Public Offering of Shares 24
G1 Therapeutics Raises USD115.3 Million in Public Offering of Shares 26
G1 Therapeutics Raises USD116.7 Million in IPO 28
G1 Therapeutics Inc, Key Competitors 30
G1 Therapeutics Inc, Key Employees 31
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.